Skip to main content
Top
Published in: Inflammopharmacology 6/2023

09-08-2023 | Rheumatoid Arthritis | Commentary

A need for clinical trial: re-purposing the Monoamine Oxidase Inhibitors (MAO-I) for rheumatoid arthritis (RA)

Author: Asis Bala

Published in: Inflammopharmacology | Issue 6/2023

Login to get access

Abstract

There is a group of enzymes called monoamine oxidase(s) (MAOs) that help with the oxidation of amines found in both our diet and our bodies. Currently, monoamine oxidase inhibitors (MAO-Is) are utilized to manage conditions like depression, Parkinson’s disease, and other psychiatric disorders. Rheumatoid arthritis (RA) is an auto-immune disease that has been linked to negative changes in mental health, such as depression. When depression co-occurs with RA, it can further worsen the outcome of the disease. Inhibiting monoamine oxidases could potentially treat RA by improving its pathological markers. Using existing pre-clinical and clinical data on safety and toxicity makes drug re-purposing advantageous. Hence, the pre-clinical validation of MAO-I’s effectiveness in managing RA requires urgent regulatory intervention to commence clinical trials. Back in 1983, a clinical case report put forward the idea of repurposing MAO-I for RA treatment. Although MAO-I had been used for depression, it was observed to have a significant reduction in joint pain and stiffness. However, no significant clinical research has been conducted on this matter since then. In this commentary article, we provide a summary of the pre-clinical data that is currently available. The main focus of our discussion is on the significance of clinical trials for MAO-I, repurposing it for RA, and using it for the simultaneous management of depression and RA.
Literature
go back to reference Callingham BA, Parkinson D (1977) The inhibition of human heart monoamine oxidase [proceedings]. Br J Pharmacol 61(3):470P-471PPubMedPubMedCentral Callingham BA, Parkinson D (1977) The inhibition of human heart monoamine oxidase [proceedings]. Br J Pharmacol 61(3):470P-471PPubMedPubMedCentral
go back to reference Kanoje V, Pandey D, Wagh A, Patra S, Marisetti AK, Reddy M, Samant C, Mahajan N, Gholve M, Sabde S, Trivedi S, Bhankhede T, Patil V, Nigade P, Modi D, Mehta M, Ahirrao P, Tota S, Nanda B, Pawar S, Polawar A, Tamane K, Kuldharan S, Vishwase G, Jana N, Mahangare SJ, Vidhate P, Lagad D, Gundu J, Phukan S, Shukla M, Narasimham L, Nemmani KVS, Bhonde M, Sharma S, Kamboj RK, Palle VP (2022) Discovery and pre-clinical characterization of a selective PI3Kδ inhibitor, LL-00071210 in rheumatoid arthritis. Eur J Pharmacol 927(2022):175054. https://doi.org/10.1016/j.ejphar.2022.175054CrossRefPubMed Kanoje V, Pandey D, Wagh A, Patra S, Marisetti AK, Reddy M, Samant C, Mahajan N, Gholve M, Sabde S, Trivedi S, Bhankhede T, Patil V, Nigade P, Modi D, Mehta M, Ahirrao P, Tota S, Nanda B, Pawar S, Polawar A, Tamane K, Kuldharan S, Vishwase G, Jana N, Mahangare SJ, Vidhate P, Lagad D, Gundu J, Phukan S, Shukla M, Narasimham L, Nemmani KVS, Bhonde M, Sharma S, Kamboj RK, Palle VP (2022) Discovery and pre-clinical characterization of a selective PI3Kδ inhibitor, LL-00071210 in rheumatoid arthritis. Eur J Pharmacol 927(2022):175054. https://​doi.​org/​10.​1016/​j.​ejphar.​2022.​175054CrossRefPubMed
go back to reference Sur D, Dutta A, Mondal C, Banerjee A, Haldar PK, Maji HS, Bala A (2022) Repurposing monoamine oxidase inhibitors (MAOI) for the treatment of rheumatoid arthritis possibly through modulating reactive oxidative stress-mediated inflammatory cytokines. Inflammopharmacol 30(2):453–463. https://doi.org/10.1007/s10787-022-00945-9CrossRef Sur D, Dutta A, Mondal C, Banerjee A, Haldar PK, Maji HS, Bala A (2022) Repurposing monoamine oxidase inhibitors (MAOI) for the treatment of rheumatoid arthritis possibly through modulating reactive oxidative stress-mediated inflammatory cytokines. Inflammopharmacol 30(2):453–463. https://​doi.​org/​10.​1007/​s10787-022-00945-9CrossRef
go back to reference Sur D, Mondal C, Balaraman AK, Haldar PK, Maji HS, Bala A (2023) Attenuation of COX-2 enzyme by modulating H2O2-mediated NF-κB signaling pathway by monoamine oxidase inhibitor (MAOI): a further study on the reprofiling of MAOI in acute inflammation. Inflammopharmacol 31(3):1305–1317. https://doi.org/10.1007/s10787-023-01165-5CrossRef Sur D, Mondal C, Balaraman AK, Haldar PK, Maji HS, Bala A (2023) Attenuation of COX-2 enzyme by modulating H2O2-mediated NF-κB signaling pathway by monoamine oxidase inhibitor (MAOI): a further study on the reprofiling of MAOI in acute inflammation. Inflammopharmacol 31(3):1305–1317. https://​doi.​org/​10.​1007/​s10787-023-01165-5CrossRef
Metadata
Title
A need for clinical trial: re-purposing the Monoamine Oxidase Inhibitors (MAO-I) for rheumatoid arthritis (RA)
Author
Asis Bala
Publication date
09-08-2023
Publisher
Springer International Publishing
Published in
Inflammopharmacology / Issue 6/2023
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-023-01310-0

Other articles of this Issue 6/2023

Inflammopharmacology 6/2023 Go to the issue